NEUROGENE INC (NGNE) Stock Price, Forecast & Analysis
NASDAQ:NGNE • US64135M1053
NGNE Key Statistics, Chart & Performance
The current stock price of NGNE is 17.85 USD. In the past month the price decreased by -7.11%. In the past year, price increased by 1.61%.
NGNE Technical Analysis
NGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NGNE. The financial health of NGNE is average, but there are quite some concerns on its profitability.
NGNE Financial Highlights
Over the last trailing twelve months NGNE reported a non-GAAP Earnings per Share(EPS) of -4.11. The EPS increased by 14.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.11% | ||
| ROE | -28.3% | ||
| Debt/Equity | 0 |
NGNE Forecast & Estimates
12 analysts have analysed NGNE and the average price target is 60.18 USD. This implies a price increase of 237.14% is expected in the next year compared to the current price of 17.85.
For the next year, analysts expect an EPS growth of -0.23% and a revenue growth -100% for NGNE
NGNE Ownership
NGNE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.75 | 397.325B | ||
| AMGN | AMGEN INC | 16.85 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.79 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.9 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.34 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.79 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.93 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NGNE
Company Profile
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
Company Info
NEUROGENE INC
535 W 24Th Street, 5Th Floor
New York City NEW YORK US
Employees: 107
Phone: 18772375020
NEUROGENE INC / NGNE FAQ
What does NGNE do?
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
What is the stock price of NEUROGENE INC today?
The current stock price of NGNE is 17.85 USD. The price increased by 1.19% in the last trading session.
What is the dividend status of NEUROGENE INC?
NGNE does not pay a dividend.
What is the ChartMill technical and fundamental rating of NGNE stock?
NGNE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is NEUROGENE INC (NGNE) stock traded?
NGNE stock is listed on the Nasdaq exchange.
When does NEUROGENE INC (NGNE) report earnings?
NEUROGENE INC (NGNE) will report earnings on 2026-03-23, after the market close.
Who owns NEUROGENE INC?
You can find the ownership structure of NEUROGENE INC (NGNE) on the Ownership tab.